Stock-based Compensation - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended			11 Months Ended	12 Months Ended
	Feb. 29, 2020	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Oct. 31, 2020	Oct. 19, 2020	Apr. 30, 2020	Sep. 30, 2019	Apr. 12, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares issued		12,973,145		1,174,800	12,972,815	12,973,145	12,972,815
Incremental compensation expense			$ 200,000
Remaining incremental compensation expense to be recognized			$ 100,000
Stock-based compensation expense						$ 300,000	$ 500,000
Number of stock options with reduced exercise price			4,394,999
Stock options granted						1,461,000
Unrecognized stock based compensation expense related to unvested outstanding stock options		$ 200,000				$ 200,000
Weighted average grant-date fair value, Granted						$ 0.15	$ 0.07
Fair value of options vested						$ 100,000	$ 500,000
Warrants issued								7,925,000
Warrants, exercise price					$ 0.01		$ 0.01		$ 2.50
Warrants outstanding					$ 800,000		$ 800,000
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrants issued											4,375,000
Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						$ 200,000
Contingent warrants issued				750,000
Warrants, exercise price			$ 1.50	$ 2.50
Warrants expiration period				10 years
Description of warrant						the Company issued to an employee warrants to purchase 750,000 shares of the Company’s common stock. The warrants were issued with a 10-year life and an exercise price equal to the lesser of $2.50 per share and the price at which stock options were to be granted to the Company's officers in 2021. One-third (1/3) of the warrants vested and became exercisable on the grant date, one-third (1/3) vested and became exercisable on March 31, 2021, and one-third (1/3) vested and became exercisable on June 30, 2021. During the third quarter of 2021, the exercise price of the warrants was set at $1.50 per share pursuant to the terms of the warrant agreement. Except for the reduction in exercise price, all terms and conditions of the warrants remain the same. During the year ended December 31, 2021, the Company recorded stock-based compensation expense of $0.2 million related to these warrants.
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Financing transactions, award grant						$ 30,000,000
Board of Directors [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options, term of award	10 years		10 years		10 years
Additional stock options granted			211,000		3,394,999
Stock option exercise price	$ 2.50		$ 1.50		$ 2.50		$ 2.50
Stock options granted	70,000
Stock option vest ratably years	3 years
Stock options granted, description	the Board of Directors also granted 70,000 stock options as compensation to board members with an exercise price of $2.50 per share and a 10-year life. The options vest ratably over three years. One-quarter (1/4) of the options vested and became exercisable on the grant date. The remaining vest and become exercisable ratably on the first, second, and third anniversaries of the date of grant.		the Board of Directors also granted 211,000 stock options as compensation to board members with an exercise price of $1.50 and a 10-year life. 111,000 of the options vested and became exercisable on the grant date. The remaining 100,000 stock options vest and become exercisable on the first anniversary of the date of grant.		the Board of Directors granted 3,394,999 stock options with an exercise price of $2.50 per share and a 10-year life. For 1,450,000 of the stock options granted, one-quarter (1/4) vested and became exercisable on the grant date, with the remainder vesting and becoming exercisable ratably on the first, second, and third anniversaries of the date of grant. The remaining 1,944,999 stock options granted were fully vested and exercisable on the grant date.
Fully vested and exercisable number of remaining stock options granted			100,000		1,944,999		1,944,999
Partly vested and exercisable number of remaining stock options granted			111,000		1,450,000		1,450,000
Employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options, term of award		10 years	10 years
Additional stock options granted		500,000	750,000
Stock option exercise price		$ 1.50	$ 1.50			$ 1.50
Stock options granted, description		the Board of Directors granted an employee 500,000 stock options with an exercise price of $1.50 per share and a 10-year life. One-quarter (1/4) of the options vested and became exercisable on the grant date. The remaining 375,000 stock option vest and become exercisable ratably on the first, second and third anniversaries of the date of grant.	the Board of Directors granted an employee 750,000 stock options with an exercise price of $1.50 per share and a 10-year life. One-third (1/3) of the options vested and became exercisable on the grant date, one-third (1/3) vest and become exercisable approximately 11 months after the date of grant, and one-third (1/3) vest and become exercisable approximately 23 months after the date of grant.
Fully vested and exercisable number of remaining stock options granted		375,000				375,000
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares issued												4,250,000
Options available for grant												6,250,000
Stock Options [Member] | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of aggregate shares purchased						0	800,000
Stock Options [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options, term of award						10 years
Stock Incentive Plan [Member] | Board of Directors [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares approved and available under stock option	9,250,000									12,000,000